Literature DB >> 24339336

Modulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimetic.

Roberto Cighetti1, Carlotta Ciaramelli, Stefania Enza Sestito, Ivan Zanoni, Łukasz Kubik, Ana Ardá-Freire, Valentina Calabrese, Francesca Granucci, Roman Jerala, Sonsoles Martín-Santamaría, Jesus Jiménez-Barbero, Francesco Peri.   

Abstract

Monosaccharide lipid A mimetics based on a glucosamine core linked to two fatty acid chains and bearing one or two phosphate groups have been synthesized. Compounds 1 and 2, each with one phosphate group, were practically inactive in inhibiting LPS-induced TLR4 signaling and cytokine production in HEK-blue cells and murine macrophages, but compound 3, with two phosphate groups, was found to be active in efficiently inhibiting TLR4 signal in both cell types. The direct interaction between compound 3 and the MD-2 coreceptor was investigated by NMR spectroscopy and molecular modeling/docking analysis. This compound also interacts directly with the CD14 receptor, stimulating its internalization by endocytosis. Experiments on macrophages show that the effect on CD14 reinforces the activity on MD-2·TLR4 because compound 3's activity is higher when CD14 is important for TLR4 signaling (i.e., at low LPS concentration). The dual targeting of MD-2 and CD14, accompanied by good solubility in water and lack of toxicity, suggests the use of monosaccharide 3 as a lead compound for the development of drugs directed against TLR4-related syndromes.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  NMR; bioorganic chemistry; carbohydrates; drug design; molecular modeling

Mesh:

Substances:

Year:  2013        PMID: 24339336      PMCID: PMC4040397          DOI: 10.1002/cbic.201300588

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  36 in total

Review 1.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2.

Authors:  J da Silva Correia; K Soldau; U Christen; P S Tobias; R J Ulevitch
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

Review 3.  TLR4 as the mammalian endotoxin sensor.

Authors:  B Beutler
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

Review 4.  Identification of Toll-like receptor 4 (Tlr4) as the sole conduit for LPS signal transduction: genetic and evolutionary studies.

Authors:  B Beutler; X Du; A Poltorak
Journal:  J Endotoxin Res       Date:  2001

5.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.

Authors:  F Granucci; C Vizzardelli; N Pavelka; S Feau; M Persico; E Virzi; M Rescigno; G Moro; P Ricciardi-Castagnoli
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

6.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

7.  Rough and smooth forms of fluorescein-labelled bacterial endotoxin exhibit CD14/LBP dependent and independent binding that is influencedby endotoxin concentration.

Authors:  M Triantafilou; K Triantafilou; N Fernandez
Journal:  Eur J Biochem       Date:  2000-04

8.  Divergent response to LPS and bacteria in CD14-deficient murine macrophages.

Authors:  K J Moore; L P Andersson; R R Ingalls; B G Monks; R Li; M A Arnaout; D T Golenbock; M W Freeman
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

9.  Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4.

Authors:  Riyoko Tamai; Yasuyuki Asai; Masahito Hashimoto; Koichi Fukase; Shoichi Kusumoto; Hideharu Ishida; Makoto Kiso; Tomohiko Ogawa
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

10.  The TLR4 antagonist Eritoran protects mice from lethal influenza infection.

Authors:  Kari Ann Shirey; Wendy Lai; Alison J Scott; Michael Lipsky; Pragnesh Mistry; Lioubov M Pletneva; Christopher L Karp; Jaclyn McAlees; Theresa L Gioannini; Jerrold Weiss; Wilbur H Chen; Robert K Ernst; Daniel P Rossignol; Fabian Gusovsky; Jorge C G Blanco; Stefanie N Vogel
Journal:  Nature       Date:  2013-05-01       Impact factor: 49.962

View more
  14 in total

1.  Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis.

Authors:  Fabio Alessandro Facchini; Davide Di Fusco; Simona Barresi; Andrea Luraghi; Alberto Minotti; Francesca Granucci; Giovanni Monteleone; Francesco Peri; Ivan Monteleone
Journal:  Eur J Clin Pharmacol       Date:  2020-01-25       Impact factor: 2.953

2.  TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection.

Authors:  Laure Perrin-Cocon; Anne Aublin-Gex; Stefania E Sestito; Kari Ann Shirey; Mira C Patel; Patrice André; Jorge C Blanco; Stefanie N Vogel; Francesco Peri; Vincent Lotteau
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

Review 3.  The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling.

Authors:  Florent Cochet; Francesco Peri
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

4.  Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiation.

Authors:  Chiara Grasselli; Daniela Ferrari; Cristina Zalfa; Matias Soncini; Gianluigi Mazzoccoli; Fabio A Facchini; Laura Marongiu; Francesca Granucci; Massimiliano Copetti; Angelo Luigi Vescovi; Francesco Peri; Lidia De Filippis
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

5.  Co-administration of Antimicrobial Peptides Enhances Toll-like Receptor 4 Antagonist Activity of a Synthetic Glycolipid.

Authors:  Fabio A Facchini; Helena Coelho; Stefania E Sestito; Sandra Delgado; Alberto Minotti; David Andreu; Jesús Jiménez-Barbero; Francesco Peri
Journal:  ChemMedChem       Date:  2018-01-24       Impact factor: 3.466

6.  Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly properties.

Authors:  Florent Cochet; Fabio A Facchini; Lenny Zaffaroni; Jean-Marc Billod; Helena Coelho; Aurora Holgado; Harald Braun; Rudi Beyaert; Roman Jerala; Jesus Jimenez-Barbero; Sonsoles Martin-Santamaria; Francesco Peri
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

Review 7.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.

Authors:  Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri
Journal:  Vaccines (Basel)       Date:  2017-10-04

Review 8.  Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.

Authors:  Alessio Romerio; Francesco Peri
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

9.  The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling.

Authors:  Charys Palmer; Francesco Peri; Frank Neumann; Feroz Ahmad; David S Leake; Grisha Pirianov
Journal:  Innate Immun       Date:  2018-09-12       Impact factor: 2.680

Review 10.  Targeting TLR4 Signaling to Blunt Viral-Mediated Acute Lung Injury.

Authors:  Kari Ann Shirey; Jorge C G Blanco; Stefanie N Vogel
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.